Alteration of Plasma Metabolites Associated with Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma Via Untargeted Metabolomics Approach

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2020 Sep 4

PMID 32878621

Citations 6

Authors

Yaowen Zhang

Jianpo Wang

Ningtao Dai

Peng Han

Jian Li

Jiangman Zhao

Weilan Yuan

Jiahuan Zhou

Fuyou Zhou

Affiliations

Soon will be listed here.

Abstract

Background: To investigate the differences in plasma metabolomic characteristics between pathological complete response (pCR) and non-pCR patients and identify biomarker candidates for predicting the response to neoadjuvant chemoradiotherapy (nCRT) in esophageal squamous cell carcinoma (ESCC).

Methods: A total of 46 ESCC patients were included in this study. Gas chromatography time-of- flight mass spectrometry (GC-TOF/MS) technology was applied to detect the plasma samples collected before nCRT via untargeted metabolomics analysis.

Results: Five differentially expressed metabolites (out of 109) was found in plasma between pCR and non-pCR groups. Compared with non-pCR group, isocitric acid (p = 0.0129), linoleic acid (p = 0.0137), citric acid (p = 0.0473) were upregulated, while L-histidine (p = 0.0155), 3'4 dihydroxyhydrocinnamic acid (p = 0.0339) were downregulated in the pCR plasma samples. Pathway analyses unveiled that citrate cycle (TCA cycle), glyoxylate and dicarboxylate metabolic pathway were associated with ESCC chemoradiosensitivity.

Conclusion: The present study provided supporting evidence that GC-TOF/MS based metabolomics approach allowed identification of metabolite differences between pCR and non-pCR patients in plasma levels, and the systemic metabolic status of patients may reflect the response of ESCC patient to neoadjuvant chemoradiotherapy.

Citing Articles

Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics.

Yang J, Zhu Y, Zhou Y, Zhang J, Wei Y, Liu Y BMC Cancer. 2025; 25(1):438.

PMID: 40069698 PMC: 11900641. DOI: 10.1186/s12885-025-13866-x.

Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring.

Wang W, Zhen S, Ping Y, Wang L, Zhang Y Front Oncol. 2024; 14:1331215.

PMID: 38384814 PMC: 10879439. DOI: 10.3389/fonc.2024.1331215.

Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer.

Jayakrishnan T, Mariam A, Farha N, Rotroff D, Aucejo F, Barot S Sci Rep. 2024; 14(1):4294.

PMID: 38383634 PMC: 10881959. DOI: 10.1038/s41598-024-54560-5.

Preliminary Findings on the Salivary Metabolome of Hookah and Cigarette Smokers.

Greenfield E, Alves M, Rodrigues F, Nogueira J, da Silva L, de Jesus H ACS Omega. 2023; 8(40):36845-36855.

PMID: 37841134 PMC: 10569005. DOI: 10.1021/acsomega.3c03683.

Microbiome and metabolic features of tissues and feces reveal diagnostic biomarkers for colorectal cancer.

Feng J, Gong Z, Sun Z, Li J, Xu N, Thorne R Front Microbiol. 2023; 14:1034325.

PMID: 36712187 PMC: 9880203. DOI: 10.3389/fmicb.2023.1034325.

References

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

Puchades-Carrasco L, Pineda-Lucena A . Metabolomics Applications in Precision Medicine: An Oncological Perspective. Curr Top Med Chem. 2017; 17(24):2740-2751. PMC: 5652075. DOI: 10.2174/1568026617666170707120034. View

Fujigaki S, Nishiumi S, Kobayashi T, Suzuki M, Iemoto T, Kojima T . Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach. Biomark Med. 2018; 12(8):827-840. DOI: 10.2217/bmm-2017-0449. View

DAmico T . Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res. 2009; 1(5):188-96. PMC: 2632530. View

Mamas M, Dunn W, Neyses L, Goodacre R . The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol. 2010; 85(1):5-17. DOI: 10.1007/s00204-010-0609-6. View

Borggreve A, Mook S, Verheij M, Mul V, Bergman J, Bartels-Rutten A . Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. BMC Cancer. 2018; 18(1):1006. PMC: 6195948. DOI: 10.1186/s12885-018-4892-6. View

Yu J, Hou M, Pei T . Is a Prognosis Signature and Potential Oncogene of Lung Adenocarcinoma. DNA Cell Biol. 2020; 39(5):890-899. DOI: 10.1089/dna.2019.4970. View

Chen M, Chen P, Lu M, Lee C, Chen W . Survival benefit of surgery to patients with esophageal squamous cell carcinoma. Sci Rep. 2017; 7:46139. PMC: 5382669. DOI: 10.1038/srep46139. View

Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Manolakou S, Messaritakis I . PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer. Cancers (Basel). 2020; 12(8). PMC: 7465271. DOI: 10.3390/cancers12082058. View

10.

Buas M, Gu H, Djukovic D, Zhu J, Onstad L, Reid B . Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Metabolomics. 2017; 13(3). PMC: 5295138. DOI: 10.1007/s11306-016-1154-y. View

11.

Ping F, Guo Y, Cao Y, Shang J, Yao S, Zhang J . Metabolomics Analysis of the Renal Cortex in Rats With Acute Kidney Injury Induced by Sepsis. Front Mol Biosci. 2020; 6:152. PMC: 6934034. DOI: 10.3389/fmolb.2019.00152. View

12.

Rice T, Ishwaran H, Ferguson M, Blackstone E, Goldstraw P . Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer. J Thorac Oncol. 2016; 12(1):36-42. PMC: 5591443. DOI: 10.1016/j.jtho.2016.10.016. View

13.

Tsai C, Yeh T, Wu R, Lai Y, Chiang M, Lu K . Metabolomic alterations and chromosomal instability status in gastric cancer. World J Gastroenterol. 2018; 24(33):3760-3769. PMC: 6127658. DOI: 10.3748/wjg.v24.i33.3760. View

14.

Abdel-Wahab A, Mahmoud W, Al-Harizy R . Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019; 150:104511. DOI: 10.1016/j.phrs.2019.104511. View

15.

Arima K, Lau M, Zhao M, Haruki K, Kosumi K, Mima K . Metabolic Profiling of Formalin-Fixed Paraffin-Embedded Tissues Discriminates Normal Colon from Colorectal Cancer. Mol Cancer Res. 2020; 18(6):883-890. PMC: 7272267. DOI: 10.1158/1541-7786.MCR-19-1091. View

16.

Yu Y, Gao Z, Lou J, Mao Z, Li K, Chu C . Identification of Serum-Based Metabolic Feature and Characteristic Metabolites in Paraquat Intoxicated Mouse Models. Front Physiol. 2020; 11:65. PMC: 7017841. DOI: 10.3389/fphys.2020.00065. View

17.

Sun L, Suo C, Li S, Zhang H, Gao P . Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim Biophys Acta Rev Cancer. 2018; 1870(1):51-66. DOI: 10.1016/j.bbcan.2018.06.005. View

18.

Xi Y, Yuefen P, Wei W, Quan Q, Jing Z, Jiamin X . Analysis of prognosis, genome, microbiome, and microbial metabolome in different sites of colorectal cancer. J Transl Med. 2019; 17(1):353. PMC: 6819376. DOI: 10.1186/s12967-019-2102-1. View

19.

Chiu C, Zhang P, Chang A, Derstine B, Ross B, Enchakalody B . Morphomic Factors Associated With Complete Response to Neoadjuvant Therapy in Esophageal Carcinoma. Ann Thorac Surg. 2019; 109(1):241-248. PMC: 7150584. DOI: 10.1016/j.athoracsur.2019.08.031. View

20.

Creighton C, Hanash S, Beer D . Gene expression patterns define pathways correlated with loss of differentiation in lung adenocarcinomas. FEBS Lett. 2003; 540(1-3):167-70. DOI: 10.1016/s0014-5793(03)00259-x. View